LY2875358
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for LY2875358, covering 2015-01-16 to 2026-01-26. Get the full timeline:
Most recent: Clinical Trial Update: A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [Phase 2]